Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) Retrospectively and Prospectively as First Line Treatment for Patients With Advanced or Metastatic Non Small Cell Lung Cancer. Assessment of Toxicity, Compliance and Survival of Patients.
Phase of Trial: Phase IV
Latest Information Update: 01 Aug 2016
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 23 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Sep 2013 New trial record